SCHEMBL358058

SCHEMBL358058

C[C@H](CO)Cc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 4/20 0.65
TAAR1 Q96RJ0 4/20 0.54
SIGMAR1 Q99720 4/20 0.54
SLC6A2 P23975 2/20 0.54
MAOA P21397 1/20 0.54
SLC6A4 P31645 1/20 0.54
SLC6A3 Q01959 1/20 0.54
CYP2A6 P11509 1/20 0.54
ADORA2A P29274 1/20 0.54
ADORA1 P30542 1/20 0.54
SLC18A2 Q05940 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP3A4 P08684 1/20 0.49
MAPK1 P28482 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
ALPL P05186 1/20 0.47
POLB P06746 1/20 0.47
ALPG P10696 1/20 0.47
MDM2 Q00987 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1911102 1.00 TRPA1 (0.65) TRPA1TAAR1SIGMAR1SLC6A2MAOA
SCHEMBL94629 1.00 TRPA1 (0.65) TRPA1TAAR1SIGMAR1SLC6A2MAOA
SCHEMBL110694 0.89 TRPA1 (0.59) TRPA1TAAR1SIGMAR1SLC6A2MAOA
SCHEMBL17171333 0.89 TRPA1 (0.59) TRPA1TAAR1SIGMAR1SLC6A2MAOA
SCHEMBL8283173 0.87 TRPA1 (0.52) TRPA1CYP2D6
Phthalic Acid SCHEMBL28282618 0.87 TRPA1 (0.52) TRPA1CYP3A4MAPK1NPC1RAB9A
SCHEMBL4785594 0.85 SIGMAR1 (0.64) TRPA1TAAR1SIGMAR1SLC6A2MAOA
SCHEMBL11434236 0.82 LTA4H (0.58) TRPA1
SCHEMBL357349 0.82 MAOB (0.57) SIGMAR1SLC6A2MAOASLC6A3
SCHEMBL360368 0.82 MAOB (0.57) SIGMAR1SLC6A2MAOASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702444-B2 Method for preparing natural bioactive peptide Tubulysin U SHENZHEN INSTITUTE OF GERIATRICS (CN) 2023-07-18 US disclosed
US-11685734-B2 ATM kinase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2023-06-27 US disclosed
EP-3906232-B1 PROCESS FOR THE DIFFERENTIAL SOLUBILITY-DRIVEN ASYMMETRIC TRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXYLIC ACIDS ASKAT INC (JP) 2023-05-10 EP disclosed
US-20190248785-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG SHIONOGI & CO., LTD. (JP) 2019-08-15 US disclosed
EP-2791142-B1 COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS US HEALTH (US) 2019-07-03 EP disclosed
WO-2018140630-A1 AUTOPHAGY INDUCERS FOR TREATMENT OF CNS CONDITIONS NORTHWESTERN UNIVERSITY (US) 2018-08-02 WO disclosed
US-20180170889-A1 Simplified Structural Mimetics of AIPS as Quorum Sensing Inhibitors WISCONSIN ALUMNI RESEARCH FOUNDATION 2018-06-21 US disclosed
US-9815835-B2 Substituted polycyclic carbamolypyridone derivative SHIONOGI & CO., LTD. (JP) 2017-11-14 US disclosed
US-20170260192-A1 COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES (US) 2017-09-14 US disclosed
US-9758515-B2 Substituted polycyclic carbamoyl pyridone derivative prodrug SHIONOGI & CO., LTD. (JP) 2017-09-12 US disclosed
WO-2007121920-A2 PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007121923-A1 PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007103755-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed
EP-1534712-B1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORP (US) 2007-05-16 EP disclosed
US-7189864-B2 Method of preparing intermediates useful in synthesis of retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-03-13 US disclosed
WO-2006021213-A2 VASOPRESSIN V1A ANTAGONISTS FERRING B.V. (NL) 2006-03-02 WO disclosed
EP-0817770-A1 NONPEPTIDES AS TACHYKININ ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1998-01-14 EP disclosed
EP-0492401-B1 Asymmetric hydrogenation CIBA GEIGY AG (CH) 1996-01-24 EP disclosed
US-5288928-A Using neutal or cationic rhodium complex of a chiral atropisomeric diphosphine ligand as catalyst CIBA-GEIGY CORPORATION (US) 1994-02-22 US disclosed
EP-0492401-A1 Asymmetric hydrogenation CIBA-GEIGY AG (CH) 1992-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260192-A1 COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS PGF, BRCA1, RB1 TRPA1 3313/4885TAAR1 3340/4885SIGMAR1 2349/4885
US-11685734-B2 ATM kinase inhibitors and compositions and methods of use thereof ATM, CHEK2, CHEK1 TRPA1 4790/4885TAAR1 4112/4885SIGMAR1 4716/4885
US-20190248785-A1 SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG PREP, UNG, DPP4 TRPA1 4750/4885TAAR1 4505/4885SIGMAR1 2781/4885
US-20180170889-A1 Simplified Structural Mimetics of AIPS as Quorum Sensing Inhibitors AIP, AIPL1, CGAS TRPA1 993/4885TAAR1 3070/4885SIGMAR1 3642/4885
US-11702444-B2 Method for preparing natural bioactive peptide Tubulysin U VIP, MLN, HNRNPU TRPA1 729/4885TAAR1 257/4885SIGMAR1 3052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.